IP Library Granted Patent US 8,592,227
Granted Patent B2
US 8,592,227 · App. 13/068,174 · Granted Nov 26, 2013

Hybrid quantum dot/protein nanostructure, methods of making, and methods of use thereof

Inventors: Nan Ma (Mountain View, CA); Jianghong Rao (Sunnyvalle, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,592,227
App. No.
13/068,174
Granted
Nov 26, 2013
Kind
B2
Abstract

Embodiments of the present disclosure include hybrid quantum dot/protein nanostructure, hybrid quantum dot/protein nanostructure systems, methods of using hybrid quantum dot/protein nanostructures, and the like.

Claims (13)

1. A method of making a hybrid quantum dot/protein nanostructure, comprising:

introducing a first precursor compound to a bioluminescence protein in a solution, wherein the precursor compound includes a first atom, wherein the bioluminescence protein bonds to a plurality of first atoms to form first atom-bioluminescence protein complexes; and

introducing a second precursor compound to the solution including the first atom-bioluminescence protein complexes to form the hybrid quantum dot/protein nanostructure, wherein the second precursor compound includes a second atom, wherein the first atom and the second atom interact to form a quantum dot core, wherein the quantum dot core has a plurality of bioluminescence proteins each bonded to a plurality of first atoms.

2. The method of claim 1 , wherein the introduction of the first precursor compound and the introduction of the second precursor compound are conducted in the same reaction vessel.

3. The method of claim 1 , wherein the introduction of the first precursor compound into the solution and the introduction of the second precursor compound into the solution are conducted without separating the first atom-bioluminescence protein complexes from the solution prior to introducing the second precursor compound into the solution.

4. The method of claim 1 , wherein the first atom is selected from the group consisting of: Pb and Cd.

5. The method of claim 1 , wherein the second atom is selected from the group consisting of: S and Se.

6. The method of claim 1 , wherein the first atom is Pb and the second atom is S.

7. The method of claim 1 , wherein the bioluminescence donor molecule is a Luciferase protein.

8. The method of claim 1 , wherein the bioluminescence donor molecule is selected from a Renilla Luciferase protein, a mutated Renilla Luciferase protein, and a combination thereof.

9. The method of claim 1 , wherein the bioluminescence donor molecule is a mutated Renilla Luciferase protein SEQ ID NO: 2.

10. The method of claim 1 , wherein the core quantum dot is selected from the group consisting of: PbS, CdS, and CdSe.

11. The method of claim 1 , wherein the core of the quantum dot is selected from: a IIB-VIA semiconductor, a IIIA-VA semiconductor, and a IVA-VIA semiconductor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2011
From: MA, NAN; RAO, JIANGHONG
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 026691/0850 →
CONFIRMATORY LICENSE Recorded Jun 9, 2011
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026413/0759 →
Continuity (2)
Provisional Application 61330931 · May 4, 2010
Related Publication 20110278554A1 · Nov 17, 2011